|
|
|
|
S-1 Monotherapy in Patients with Advanced Biliary Tract Cancer
bEndoscopy and Endoscopic Surgery, Faculty of Medicine, University of Tokyo, cDepartment of Gastroenterology, Japanese Red Cross Medical Center, Tokyo, Japan Oncology 2009;77:71-74 (DOI: 10.1159/000226214) Key Words S-1 Biliary tract cancer...
|
|
|
Micromet's phase-2 study of blinatumomab in acute lymphoblastic leukaemia meets primary endpoint
Micromet, Inc, a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that the German Multicenter ALL Study Group (GMALL) presented phase-2 clinical...
|
|
|
Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymp
BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc.(NASDAQ:MITI) , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, last week presented an update...
|
|
|
Medical News: Micromet Presents Update On Blinatumomab's Response Rate And Duration In A Phase 1 Study In Non-
Also Included In: Clinical Trials / Drug Trials; Pharma Industry / Biotech Industry email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: Health Professional: Article Opinions:...
|
|
|
Micromet Presents Update On Blinatumomab's Response Rate And Duration In A Phase 1 Study In Non-Hodgkin's Lymp
Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, last week presented an update from an ongoing clinical study of the BiTE...
|
|
|
[Neurooncology] Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Tem
Purpose: Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both.The goal...
|
|
|
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
/PRNewswire-FirstCall via COMTEX/ -- MITI | Quote | Chart | News | PowerRating -- Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune...
|
|
|
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that the German Multicenter ALL Study Group (GMALL) presented...
|
|
|
Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymp
Data Presented at Meeting of European Hematology Association Confirms High Response Rate and Durability of Remissions The poster presentation gave an update of an ongoing phase 1 trial of blinatumomab in relapsed NHL patients including a...
|
|
|
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease The patients included in this phase 2 clinical trial were in...
|
|
|
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that the German Multicenter ALL Study Group (GMALL) presented...
|
|
|
Genasense Combined with Temodar and Abraxane Shows Preliminary Evidence of High Response Rates and Extended Su
- Genta Incorporated (OTCBB: GNTA) announced preliminary results that show a high objective response rate and potentially extended survival in an ongoing pilot study that incorporates the Company's lead oncology product, Genasense ...
|
|
|
Genasense, Combined with Temodar, and Abraxane, Shows Preliminary Evidence of High Response Rates
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)-- Genta Incorporated (OTCBB: GNTA) announced preliminary results that show a high objective response rate and potentially extended survival in an ongoing pilot study that incorporates the Company??s...
|
|
|
Genasense Combined with Temodar and Abraxane Shows Preliminary Evidence of High Response Rates and Exten
- Genta Incorporated (OTCBB: GNTA) announced preliminary results that show a high objective response rate and potentially extended survival in an ongoing pilot study that incorporates the Companys lead oncology product, Genasense (oblimersen...
|
|
|
Genasense Combined with Temodar and Abraxane Shows Preliminary Evidence of High Response Rates and Exten
Genta Incorporated (OTCBB: GNTA) announced preliminary results that show a high objective response rate and potentially extended survival in an ongoing pilot study that incorporates the Companys lead oncology product, Injection, in a...
|
|
|
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or pr
51 pts were entered; 259 cycles of pemetrexed were administered, with 40% of pts receiving 6 cycles.Treatment was well tolerated. More serious toxicities (grade 3/4) included neutropenia in 42%, leukopenia in 25%, anemia in 15%,...
|
|
|
Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck rece
Cancer Chemotherapy and Pharmacology, 05/29/09 Yang MH et al.- In a trial to examine the efficacy and safety of gemcitabine in combination with cisplatin (GC) as first-line treatment in pts with recurrent/metastatic (R/M) squamous cell...
|
